Abstract
Demonstration of BRAF-V600E in Rosai-Dorfman-Destombes disease requires sensitive molecular assays and molecular-based tissue immunostain.
BRAF-V600E blood testing is important for disease-monitoring BRAF-mutated histiocytosis and can guide inhibitor treatment plans.
Publication types
-
Case Reports
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Child
-
Child, Preschool
-
Female
-
Fluorodeoxyglucose F18 / metabolism
-
Histiocytosis, Langerhans-Cell / complications
-
Histiocytosis, Langerhans-Cell / diagnostic imaging
-
Histiocytosis, Langerhans-Cell / drug therapy*
-
Histiocytosis, Langerhans-Cell / genetics
-
Histiocytosis, Sinus / complications
-
Histiocytosis, Sinus / diagnostic imaging
-
Histiocytosis, Sinus / drug therapy*
-
Histiocytosis, Sinus / genetics
-
Humans
-
Imidazoles / administration & dosage
-
Imidazoles / therapeutic use
-
Infant
-
Magnetic Resonance Imaging / methods
-
Male
-
Middle Aged
-
Mutation
-
Oximes / administration & dosage
-
Oximes / therapeutic use
-
Positron Emission Tomography Computed Tomography / methods
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / therapeutic use
-
Proto-Oncogene Proteins B-raf / blood
-
Proto-Oncogene Proteins B-raf / drug effects
-
Proto-Oncogene Proteins B-raf / metabolism*
-
Treatment Outcome
Substances
-
Imidazoles
-
Oximes
-
Protein Kinase Inhibitors
-
Fluorodeoxyglucose F18
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf
-
dabrafenib